This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up
by Zacks Equity Research
J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.
Best Income Stocks to Buy for November 15th
by Zacks Equity Research
LADR, GSK, ATCO, and FRG made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 15, 2021.
Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint
by Zacks Equity Research
Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.
Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.
AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.
Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.
Best Income Stocks to Buy for November 11th
by Zacks Equity Research
BX, COP, and GSK made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 11, 2021.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GSK) Outperforming Other Medical Stocks This Year?
Bayer's (BAYRY) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Bayer's (BAYRY) earnings in the third quarter of 2021 beat estimates. Revenues surge year over year.
Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.
Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up
by Zacks Equity Research
Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.
Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.
Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Company News for Oct 28, 2021
by Zacks Equity Research
Companies in The News Are: KO,MCD,GSK,IP
Glaxo (GSK) Beats Earnings and Revenues Estimates in Q3
by Indrajit Bandyopadhyay
Glaxo (GSK) beats earnings as well as revenues estimates in the third quarter of 2021. Stock up.
Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.
The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline
Top Analyst Reports for Tesla, Johnson & Johnson & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Johnson & Johnson (JNJ), and PayPal Holdings, Inc. (PYPL).
Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters
by Kinjel Shah
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.